The PE Ratio as of December 2024 (TTM) for Innate Pharma S.A. (IPHA) is -4.68

According to Innate Pharma S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -4.68. This represents a change of -36.11% compared to the average of -7.33 of the last 4 quarters.

Innate Pharma S.A. (IPHA) Historical PE Ratio (quarterly & annually)

How has IPHA PE Ratio performed in the past?

The mean historical PE Ratio of Innate Pharma S.A. over the last ten years is 1.49. The current -4.68 PE Ratio has changed -31541.87% with respect to the historical average. Over the past ten years (40 quarters), IPHA's PE Ratio was at its highest in in the December 2015 quarter at 357.37. The PE Ratio was at its lowest in in the March 2016 quarter at -101.42.

Innate Pharma S.A. (IPHA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Innate Pharma S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innate Pharma S.A. (IPHA) Average PE Ratio

How has IPHA PE Ratio performed in the past?

The current PE Ratio of Innate Pharma S.A. (IPHA) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Innate Pharma S.A. (IPHA) PE Ratio vs. Peers

How is IPHA’s PE Ratio compared to its peers?

Innate Pharma S.A.’s PE Ratio is less than Eliem Therapeutics, Inc. (0), less than HCW Biologics Inc. (-0.41), less than Inhibrx Biosciences, Inc. (0.14), greater than Anebulo Pharmaceuticals, Inc. (-4.96), less than Pardes Biosciences, Inc. (-1.36), less than Shattuck Labs, Inc. (-0.76), greater than Champions Oncology, Inc. (-186.63), less than Century Therapeutics, Inc. (-0.67), less than Addex Therapeutics Ltd (1.05), less than Aptorum Group Limited (-1.38), less than Celyad Oncology SA (-2.42), greater than Dyadic International, Inc. (-8.11), less than Molecular Partners AG (-2.46), less than MediciNova, Inc. (-0.04), greater than Cyteir Therapeutics, Inc. (-9.12),

Build a custom stock screener for Innate Pharma S.A. (IPHA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innate Pharma S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innate Pharma S.A. (IPHA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innate Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.